We use first- and third-party cookies to provide our services and collect statistical data. By continuing to browse you accept these cookies. More information Accept
Expertise / DIFFERENTIATED PRODUCTS / Portfolio

covering a to z drugs

From AMANTADINE to ZOPICLONE

Portfolio

One of the most extensive product portfolios in CNS drugs in Europe to offer patients
and medical specialists affordable cutting-edge CNS drugs
  • Comprehensive marketed CNS portfolio of >100 molecules in all major categories
  • Unique molecules in the market
  • Added value dosage forms and strengths
  • Cross-country synergies in portfolio
  • Our strength as a Group comes from offering one of the most extensive product portfolios in CNS drugs in Europe
  • We are current leaders(*) in Antiepileptics, Antiparkinson, Antipsychotics, Antidepressants and Antialzheimer 
    and we continue to grow in other therapies
  • Our product portfolio includes >100 molecules in the categories of Analgesics, Antidementia agents, Antidepressants, Antiepileptics, Antiparkinson agents, Antipsychotics, Anxiolytics/Hypnotics and other CNS categories

(*) Source: MIDAS Q2/2017

  • We are experts in improving existing pharmaceutical forms and in upgrading new products. In some cases, new patient-friendly products and formulations are developed at the request of, and in close consultation with, medical specialists

  • Our extensive portfolio includes not only high-turnover products and conventional pharmaceutical forms but, thanks to the Group’s intense patient focus, we can also provide less popular preparations and offer products in a comprehensive, patient-friendly range of active substances in well-tolerated forms, along with a very wide range of dosages for personalised treatment


  • It is part of NuPharm Group’s very identity to be able to offer patients and medical specialists affordable cutting-edge CNS drugs

  • Medicines are improved by innovative advancements in their pharmaceutical forms and by more practical dosing



  • The integration of all the companies within NuPharm Group allows us to establish both growth and cross-business synergies in many strategic aspects such as R&D, manufacturing, procurement, cross-licensing and geographical expansion